Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P06734
UPID:
FCER2_HUMAN
Alternative names:
BLAST-2; C-type lectin domain family 4 member J; Fc-epsilon-RII; Immunoglobulin E-binding factor; Lymphocyte IgE receptor
Alternative UPACC:
P06734
Background:
The Low affinity immunoglobulin epsilon Fc receptor, known by alternative names such as BLAST-2, C-type lectin domain family 4 member J, and Fc-epsilon-RII, plays a pivotal role in immune response regulation. It functions as a low-affinity receptor for immunoglobulin E (IgE) and CR2/CD21, crucial for IgE production regulation and B cell differentiation. This receptor facilitates IgE-dependent antigen uptake and presentation on B cells, and activates intracellular parasite killing in macrophages through the L-Arginine-nitric oxide pathway.
Therapeutic significance:
Understanding the role of Low affinity immunoglobulin epsilon Fc receptor could open doors to potential therapeutic strategies.